Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00678119 · ClinicalTrials.gov registry record · Phase 2

Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment

A Phase 2 study of Renal Cell Carcinoma, sponsored by Argos Therapeutics.

Completed
Registry status
Phase 2
Development phase
25
Enrollment target
14
Study locations

NCT00678119 is a Phase 2 study of Renal Cell Carcinoma that has completed, run by Argos Therapeutics. The registered enrollment target is 25 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (90% lower). The trial reports 14 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00678119, a Phase 2 study of Renal Cell Carcinoma, has completed, sponsored by Argos Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
25 participants
Enrollment target
14
Study locations

Study Summary

Study to investigate an anticancer cellular immunotherapeutic, AGS-003, when used in combination with sunitinib in subjects with previously untreated advanced stage RCC.

Conditions Studied

Renal Cell Carcinoma

Interventions

  • DRUG Sunitinib
  • BIOLOGICAL AGS-003

Study Locations (14)

California

  • City of Hope - Duarte
  • UCLA - Los Angeles

Colorado

  • The Urology Center of Colorado - Denver

Georgia

  • Emory University - Atlanta

Indiana

  • The Indiana University Cancer Center - Indianapolis

Iowa

  • University of Iowa - Iowa City

Kansas

  • University of Kansas Hospital - Kansas City

Minnesota

  • University of Minnesota Cancer Center - Minneapolis

North Carolina

  • Carolina's Medical Center / Blumenthal Cancer Center - Charlotte

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2008-01
Est. Completion 2012-05
Phase Phase 2

Sponsor

Argos Therapeutics

10 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00678119

The ClinicalTrials.gov registry entry for NCT00678119 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (90% lower). The listed sponsor is Argos Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Sunitinib is the first listed.

NCT00678119 reports 14 study locations spanning 13 distinct geographic areas - top geographies include California, Colorado, Georgia.

Frequently Asked Questions

What is clinical trial NCT00678119 about?

NCT00678119 is a clinical study titled "Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment". Study to investigate an anticancer cellular immunotherapeutic, AGS-003, when used in combination with sunitinib in subjects with previously untreated advanced stage RCC.

What is the current status of trial NCT00678119?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2008-01. Estimated completion is 2012-05.

What conditions does trial NCT00678119 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma.

What interventions are being tested in trial NCT00678119?

The interventions under investigation include: Sunitinib (DRUG), AGS-003 (BIOLOGICAL).

Who is sponsoring clinical trial NCT00678119?

This trial is sponsored by Argos Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00678119 being conducted?

This trial has 14 study locations across California, Colorado, Georgia, Indiana, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Renal Cell Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.